Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23932
Title: IL33 and Mast Cells-The Key Regulators of Immune Responses in Gastrointestinal Cancers?
Austin Authors: Eissmann, Moritz F ;Buchert, Michael;Ernst, Matthias 
Affiliation: Olivia Newton-John Cancer Research Institute
La Trobe University School of Cancer Medicine, Heidelberg, VIC, Australia
Issue Date: 3-Jul-2020
metadata.dc.date: 2020-07-03
Publication information: Frontiers in Immunology 2020; 11: 1389
Abstract: The Interleukin (IL-)1 family IL33 is best known for eliciting type 2 immune responses by stimulating mast cells (MCs), regulatory T-cells (Tregs), innate lymphoid cells (ILCs) and other immune cells. MCs and IL33 provide critical control of immunological and epithelial homeostasis in the gastrointestinal (GI) tract. Meanwhile, the role of MCs in solid malignancies appears tissue-specific with both pro and anti-tumorigenic activities. Likewise, IL33 signaling significantly shapes immune responses in the tumor microenvironment, but these effects remain often dichotomous when assessed in experimental models of cancer. Thus, the balance between tumor suppressing and tumor promoting activities of IL33 are highly context dependent, and most likely dictated by the mixture of cell types responding to IL33. Adding to this complexity is the promiscuous nature by which MCs respond to cytokines other than IL33 and release chemotactic factors that recruit immune cells into the tumor microenvironment. In this review, we integrate the outcomes of recent studies on the role of MCs and IL33 in cancer with our own observations in the GI tract. We propose a working model where the most abundant IL33 responsive immune cell type is likely to dictate an overall tumor-supporting or tumor suppressing outcome in vivo. We discuss how these opposing responses affect the therapeutic potential of targeting MC and IL33, and highlight the caveats and challenges facing our ability to effectively harness MCs and IL33 biology for anti-cancer immunotherapy.
URI: http://ahro.austin.org.au/austinjspui/handle/1/23932
DOI: 10.3389/fimmu.2020.01389
PubMed URL: 32719677
Type: Journal Article
Subjects: ST2
cytokine signaling
gastrointestinal (GI) malignancies
innate immunity
interleukin 33 (IL33)
mast cell (MC)
therapy targets
tumor microenvironment (TME)
Appears in Collections:Journal articles

Show full item record

Page view(s)

8
checked on Dec 6, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.